Metagenomi, Inc. entered into a license agreement with Acuitas Therapeutics on September 29, 2025, granting a non-exclusive license for lipid nanoparticle technology. Additionally, the company terminated its agreement with Affini-T on September 30, 2025, regaining control over relevant intellectual property.